Pathologist

Other Specialists and General  Practitioners

U

R

U

R

21.1

Haematology

3705

Alkali resistant haemoglobin

4.5

112.10

3

74.73

3709

Antiglobulin test (Coombs' or trypsinzied red cells}

3.65

90.92

2.45

61.03

3710

Antibody titration

7.2

179.35

4.8

119.57

3711

Arneth count

2.25

56.05

1.5

37.37

3712

Antibody identification

8.45

210.49

5.65

140.74

3713

Bleeding time (does not Include the cost of the simplate device

6.94

172.88

4.63

115.33

3715

Buffy Layer examination

19.9

495.71

13.27

330.56

3716

Mean Cell Volume

2.25

56.05

1.5

37.37

3717

Bone marrow cytological examination only

19.9

495.7

13.27

330.56

3719

Bone marrow: Aspiration

8.4

209.24

5.6

139.50

3720

Bone marrow trephine biopsy

32.6

812.07

21.7

540.55

3721

Bone marrow aspiration and trephine biopsy (excluding histological examination)

36.8

916.69

24.5

610.30

3722

Capillary fragility: Hess

2.02

50.32

1.35

33.63

3723

Circulating anticoagulants

5.85

145.72

3.9

97.15

3724

Coagulation factor inhibitor assay

57.56

1 433.82

38.37

955.80

3726

Activated protein C resistance

26

647.66

17.3

430.94

3727

Coagulation time

3.16

78.72

2.11

52.56

3728

Anti-factor Xa Activity

53.6

1 335.18

35.7

622.75

3729

Cold agglutinins

3.6

89.68

2.4

59.78

3730

Protein S: Functional

37.5

934.13

25

622.75

3731

Compatability for blood transfusions

3.6

89.68

2.4

59.78

3734

Protein C (chromogenic)

30.29

754.52

20.19

502.93

3739

Erythrocyte count

2.25

56.05

1.5

37.37

3740

Factors v and VII: Qualitative

7.2

179.35

4.8

119.57

3741

Coagulation factor assay: functional

9.45

235.40

6.3

156.93

3742

Coagulation factor assay: Immunological

4.5

112.10

3

74.73

3743

Erythrocyte sedimentation rate

2.5

62.28

1.67

41.60

3744

Fibrin stabilising factor (urea test)

4.5

112.10

3

74.73

3746

Fibrin monomers

2.7

67.26

1.8

44.84

3748

Plasminogen Activator Inhibitor

65.95

1 642.81

43.97

1094.29

3750

Tissue Plasminogen Activator (tPA)

67.79

1 688.65

45.19

1125.68

3751

Osmotic fragility (screen)

2.25

58.05

1.5

37.37

3753

Osmotic fragility (before and after incubation)

18

448.38

12

298.92

3754

ABO Reverse Groups

5.5

137.01

3.67

91.42

3755

Full blood count (including items 3739, 3762, 3783, 3785, 3791)

10.5

261.56

7

174.37

3756

Full cross match

7.2

179.35

4.8

119.57

3757

Coagulation factors (quantitative)

32.2

802.10

21.47

534.82

3758

Factor VIII related antigen

60.46

1 506.06

40.31

1004.12

3759

Coagulation factor correction study

11.72

291.95

7.81

194.55

3761

Factor XIII related antigen

61.11

1 522.25

40.74

1014.83

3762

Haemoglobin estimation

1.8

44.84

1.2

29.89

3763

Contact activated product essay

16.2

403.54

10.8

269.03

3764

Grouping: A -. B- and 0-antigens

3.6

89.68

2.4

59.78

3765

Grouping; Rh antigens

3.6

89.68

2.4

59.78

3766

PIVKA

43.49

1 083.34

28.99

722.14

3767

Euglobulin lysis time

25.58

637.20

17.05

424.72

3768

Haemoglobin A2 (column chromatography)

15

373.65

10

249.10

3769

HB Electrophoresis

26.82

668.09

17.88

445.39

3770

Haemoglobin -S (solubility test)

3.6

89.68

2.4

59.78

3773

Ham's acidified serum test

8

199.28

5.33

132.77

3775

Heinz bodies

8

199.28

5.33

132.77

3776

Haemosiderin in urinary sediment

2.25

56.05

1.5

37.37

3777

DELETED 2009: Heparin estimation

3781

Heparin tolerence

7.2

179.35

4.8

119.57

3783

Leucocyte differential count

6.2

154.44

4.15

103.38

3785

Leucocytes: total count

1.8

44.84

1.2

29.89

3786

QBC malaria concentration and fluorescent staining

25

622.75

16.7

416.00

3787

LE-cells

8.3

206.75

5.55

138.25

3789

Neutrophil alkaline phosphatase

28

697.48

18.7

465.82

3791

Packed cell volume: Haematocrit

1.8

44.84

1.2

29.89

3792

Plasmodium falciparum: Monoclonal immunological identlficatio

9

224.19

6

149.46

3793

Plasma haemoglobin

6.75

168.14

4.5

112.10

3794

Platelet Sensitivities

18.64

464.32

12.43

309.83

3795

Platelet aggregation per aggregant

12.14

302.41

8.09

201.52

3796

Platelet antibodies: agglutination

5.4

134.51

3.6

89.68

3797

Platelet count

2.25

56.05

1.5

37.37

3799

Platelet adhesiveness

4.5

112.10

3

74.73

3801

Prothrombin consumption

5.85

145.72

3.9

97.15

3803

Prothrombin determination (two stages)

5.85

145.72

3.9

97.15

3805

Prothrombin index

6

149.46

4

99.64

3806

Therapeutic drug level: Dosage

4.5

112.10

3

74.73

3807

Recalcification time

2.25

56.05

1.5

37.37

3809

Reticulocyte count

3

74.73

2

49.82

3811

Sickling test

2.25

56.05

1.5

37.37

3814

Sucrose lysis test for PNH

3.6

89.68

2.4

59.78

3816

T and B-cells EAC markers (limited to ONE marker only for CD418 counts)

21.1

525.60

14.07

350.48

3820

Thrombo-Elastogram

26

647.66

17.33

431.69

3825

Fibrinogen titre

3.6

89.68

2.4

59.78

3829

Glucose 6-phosphate-dehydragenase: Oualitative

8

199.28

5.33

132.77

3830

Glucose 6-phosphate-dehydrogenase: quantitativs

16

398.56

10.7

266.54

3832

Red cell pyruvate kinase: quantitative

16

398.56

10.7

266.54

3834

Red cell Rhesus phenotype

9.9

246.61

6.6

164.41

3835

Haemoglobin F in blood smear

5.85

145.72

3.9

97.15

3837

Partial thromboplastin time

5.85

145.72

3.9

97.15

3841

Thrombin time (screen)

5.85

145.72

3.9

97.15

3843

Thrombin time (serial)

7.65

190.56

5.1

127.04

3847

Haemoglobin H.

2.25

56.05

1.5

37.37

3851

Fibrin degeneration products (diffusion plate)

10.35

257.82

6.9

171.88

3853

Fibrin degeneration products (latex slide)

4.5

112.10

3

74.73

3854

XDP (Dimer test or equivalent latex slide test)

8.5

211.74

5.67

141.24

3856

D- Dimer

27.52

685.52

18.35

457.10

3855

Hemagglutination inhibition

9.9

246.61

6.6

164.41

3858

Heparin Removal

28.88

719.40

19.25

479.52